Table 2 Frequency of NPAEs with high-dose tafenoquine/chloroquine in vivax malaria patients [81]
From: Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review
Adverse event, n (%) | Tafenoquine 300 mg q.d. × 7 days (N = 18) | Tafenoquine 600 mg q.d. × 3 days (N = 19) | Tafenoquine 600 mg single dose (N = 18) | Primaquine 15 mg q.d. × 14 days (N = 12) |
|---|---|---|---|---|
Any NPAE | 8 (44) | 8 (42) | 4 (22) | 6 (50) |
Vertigo | 8 (44) | 8 (42) | 4 (22) | 3 (25) |
Headache | 4 (22) | 4 (21) | 2 (11) | 4 (33) |